Clinical Trial

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory/relapsed/progressive tumors harboring a high mutational load, focal MYC(N) amplification or ATRT-MYC subgroup as well as tumors with high tumor infiltrating lymphocytes (TILs) or a tertiary lymphoid structure (TLS).
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2019-02-08; most recent amendment 2024-02-05.
Status change: Not Yet Recruiting → Recruiting 2019-08-02
Trial Details
NCT Number NCT03838042
Lead Sponsor University Hospital Heidelberg
Collaborators: German Cancer Research Center
Conditions CNS Tumor, Solid Tumor
Enrollment 91 participants
Start Date 2020-05-26
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-07